Equities Analysts Offer Predictions for AGIO FY2027 Earnings

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Investment analysts at HC Wainwright boosted their FY2027 EPS estimates for shares of Agios Pharmaceuticals in a research note issued on Monday, April 20th. HC Wainwright analyst E. Bodnar now forecasts that the biopharmaceutical company will earn ($5.46) per share for the year, up from their prior forecast of ($5.48). HC Wainwright has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($6.58) per share. HC Wainwright also issued estimates for Agios Pharmaceuticals’ FY2028 earnings at ($4.64) EPS, FY2029 earnings at ($2.68) EPS and FY2030 earnings at $2.41 EPS.

A number of other brokerages also recently weighed in on AGIO. JPMorgan Chase & Co. increased their price target on shares of Agios Pharmaceuticals from $31.00 to $36.00 and gave the company a “neutral” rating in a report on Monday, April 6th. Leerink Partners raised their price objective on shares of Agios Pharmaceuticals from $34.00 to $40.00 and gave the stock an “outperform” rating in a report on Friday, December 26th. Bank of America reduced their price objective on shares of Agios Pharmaceuticals from $44.00 to $41.00 and set a “buy” rating for the company in a report on Tuesday. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Agios Pharmaceuticals in a report on Friday, March 27th. Finally, Wall Street Zen raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, March 22nd. Six analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $41.78.

Agios Pharmaceuticals Price Performance

Shares of Agios Pharmaceuticals stock opened at $25.74 on Thursday. Agios Pharmaceuticals has a fifty-two week low of $22.24 and a fifty-two week high of $46.00. The firm has a fifty day moving average price of $30.05 and a two-hundred day moving average price of $31.56. The company has a market cap of $1.51 billion, a PE ratio of -3.62 and a beta of 0.79.

Insider Transactions at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 3,262 shares of the firm’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $34.71, for a total value of $113,224.02. Following the completion of the sale, the insider owned 46,829 shares in the company, valued at approximately $1,625,434.59. This trade represents a 6.51% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Cecilia Jones sold 3,141 shares of the firm’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $34.71, for a total transaction of $109,024.11. Following the completion of the sale, the chief financial officer owned 54,998 shares of the company’s stock, valued at $1,908,980.58. The trade was a 5.40% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 15,582 shares of company stock worth $520,405. Corporate insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Ground Swell Capital LLC acquired a new stake in Agios Pharmaceuticals in the 1st quarter valued at about $282,000. SG Americas Securities LLC increased its position in Agios Pharmaceuticals by 23.2% in the 1st quarter. SG Americas Securities LLC now owns 57,247 shares of the biopharmaceutical company’s stock valued at $1,937,000 after acquiring an additional 10,796 shares in the last quarter. Diversified Trust Co increased its position in Agios Pharmaceuticals by 67.2% in the 1st quarter. Diversified Trust Co now owns 15,319 shares of the biopharmaceutical company’s stock valued at $518,000 after acquiring an additional 6,157 shares in the last quarter. Rockefeller Capital Management L.P. increased its position in Agios Pharmaceuticals by 31.4% in the 4th quarter. Rockefeller Capital Management L.P. now owns 21,071 shares of the biopharmaceutical company’s stock valued at $574,000 after acquiring an additional 5,033 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in Agios Pharmaceuticals in the 4th quarter valued at about $183,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.